FDA clears Novartis' triple antihypertensive drug for marketing. Print
Genetic Engineering News: FDA has approved Novartis’ Amturnide(TM) triple combination pill for the treatment of hypertension in patients whose blood pressure remains uncontrolled when taking two of the new drug’s individual components. Amturnide combines Novartis’ direct rennin inhibitor Tekturna(R)/Rasilez(R) (aliskiren), with the calcium channel blocker amlodipine and the diuretic hydrochlorothiazide.

...